The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Seraya I.V.

Aesthetic Technologies LLC (DEKA)

Murakov S.V.

Academy of Postgraduate Education of the Federal Scientific and Clinical Center of Federal Medical-Biological Agency of Russia

Bagramova G.E.

Patrice Lumumba Peoples’ Friendship University of Russia

Vasilyev S.V.

EYuTs Clinic LLC

Research of melasma treatment effectiveness by combined administration of autologous plasma, dermal optical thermolysis and radiofrequency exposure

Authors:

Seraya I.V., Murakov S.V., Bagramova G.E., Vasilyev S.V.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2024;23(4): 467‑474

DOI: 10.17116/klinderma202423041467

Read: 780 times

Buy for 300₽
Contact the author
Table of contents

RESEARCH OF MELASMA TREATMENT EFFECTIVENESS BY COMBINED ADMINISTRATION OF AUTOLOGOUS PLASMA, DERMAL OPTICAL THERMOLYSIS AND RADIOFREQUENCY EXPOSURE
RESEARCH OF MELASMA TREATMENT EFFECTIVENESS BY COMBINED ADMINISTRATION OF AUTOLOGOUS PLASMA, DERMAL OPTICAL THERMOLYSIS AND RADIOFREQUENCY EXPOSURE

To cite this article:

Seraya IV, Murakov SV, Bagramova GE, Vasilyev SV. Research of melasma treatment effectiveness by combined administration of autologous plasma, dermal optical thermolysis and radiofrequency exposure. Russian Journal of Clinical Dermatology and Venereology. 2024;23(4):467‑474. (In Russ.)
https://doi.org/10.17116/klinderma202423041467

Подписка 2025-2 (Russian Journal of Clinical Dermatology and Venereology)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Mediasphera_Net
Close metadata
Recommended articles:
Mela­sma: current aspe­cts of topi­cal correction. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(4):438-445
Clinical expe­rimental study of the effi­cacy and safety of biorevitalization using a drug based on native hyaluronic acid modi­fied by trehalose in patients with mela­sma. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(5):612-618
Iatrogenic Hype­rmelanoses in a Doctor’s Practice. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(6):730-739
Prospects for the use of ozone therapy and low-intensity laser therapy in the treatment of atro­phic pharyngitis. Russian Bulletin of Otorhinolaryngology. 2024;(4):4-13
Low-level laser therapy in multiple scle­rosis: justification and opti­mization methods of application. (Literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(5):45-56
Modern aspe­cts of photo and laser therapy for wound infe­ction in surgical practice. Piro­gov Russian Journal of Surgery. 2024;(12-2):134-138
Effect of low-intensity laser-therapy in the correction of ence­phalopathy in obstructive jaundice. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6):19-24
Treatment of Reti­cular Veins with a Long-pulsed 1064 nm Nd:YAG Laser: a Pilot Study. Journal of Venous Diso­rders. 2025;(2):70-76
Risk Factors of Hype­rpigmentation and Tela­ngiectatic Matting Persistence after Scle­rotherapy in C1 Patients. Journal of Venous Diso­rders. 2025;(2):77-82

BACKGROUND

Melasma is a multifactorial pigmentation disorder resulting from the abnormal accumulation of melanin. The localization of melasma in the face area causes aesthetic discomfort and reduces the quality of life. The issue of combined therapy with the use of autologous blood plasma (ABP) seems relevant for the treatment of melasma.

OBJECTIVE

To confirm that the injection of ABP in combination with laser and radiofrequency therapy contributes to more effective treatment of melasma than the injection of ABP separately.

MATERIAL AND METHODS

The study included 28 women aged 23-58 years with melasma. Laser and radiofrequency therapy was carried out, as well as ABP was injected in the study group (n=14). ABP was injected isolatedly in the control group (n=14). The disease severity was assessed on the IGA, MSS, GAIS scales, using the MASI and melanin and hemoglobin values. The effectiveness of applied treatment methods was determined by the decrease of specified indicators compared to the baseline.

RESULTS

Positive dynamics of assessment results on the MASI, IGA and MSS scores and values of chromophores (melanin and hemoglobin) has been noted in both groups. The effectiveness analysis confirmed the superiority of studied method relative to the comparison method: an improvement on the IGA scale has been observed in 86% of the study group patients and 31% of the control group patients, on the MSS scale ― of 100% and 23%, on the MASI ― of 100% and 69%, respectively. The compared methods are characterized by a high tolerability and have a similar safety profile.

CONCLUSION

The IGA, MSS and MASI scores, instrumental measurements, and the GAIS aesthetic improvement scores confirm that the studied treatment method exceeds control therapy by several times.

Keywords:

melasma
hyperpigmentation
laser therapy
radiofrequency therapy
autologous blood plasma

Authors:

Seraya I.V.

Aesthetic Technologies LLC (DEKA)

Murakov S.V.

Academy of Postgraduate Education of the Federal Scientific and Clinical Center of Federal Medical-Biological Agency of Russia

Bagramova G.E.

Patrice Lumumba Peoples’ Friendship University of Russia

Vasilyev S.V.

EYuTs Clinic LLC

Received:

05.04.2024

Accepted:

11.06.2024

List of references:

  1. Ogbechie-Godec OA, Elbuluk N. Melasma: an Up-to-Date Comprehensive Review. Dermatol Ther (Heidelb). 2017;7(3):305-318.  https://doi.org/10.1007/s13555-017-0194-1
  2. Kurbanova D. Prevalence problem of chloasma and melasma at women. Byulleten’ nauki i praktiki 2019;5(7):86-93. (In Russ.). https://doi.org/10.33619/2414-2948/44/09
  3. Wang WJ, Wu TY, Tu YK, Kuo KL, Tsai CY, Chie WC. The optimal dose of oral tranexamic acid in melasma: A network meta-analysis. Indian J Dermatol Venereol Leprol. 2023;89(2):189-194.  https://doi.org/10.25259/IJDVL_530_2021
  4. Liu W, Chen Q, Xia Y. New Mechanistic Insights of Melasma. Clin Cosmet Investig Dermatol. 2023;16:429-442.  https://doi.org/10.2147/CCID.S396272
  5. Handel AC, Miot LD, Miot HA. Melasma: a clinical and epidemiological review. An Bras Dermatol. 2014;89(5):771-782.  https://doi.org/10.1590/abd1806-4841.20143063
  6. Rossijskoe obshchestvo dermatovenerologov i kosmetologov. Khloazma: klinicheskie rekomendatsii po dermatovenerologii i kosmetologii. 2022. (In Russ.).
  7. Artzi O, Horovitz T, Bar-Ilan E, Shehadeh W, Koren A, Zusmanovitch L, Mehrabi JN, Salameh F, Isman Nelkenbaum G, Zur E, Sprecher E, Mashiah J. The pathogenesis of melasma and implications for treatment. J Cosmet Dermatol. 2021;20(11):3432-3445. https://doi.org/10.1111/jocd.14382
  8. Rajanala S, Maymone MBC, Vashi NA. Melasma pathogenesis: a review of the latest research, pathological findings, and investigational therapies. Dermatol Online J. 2019;25(10):13030/qt47b7r28c
  9. Mirzoeva MKh, Mukhamadieva KM, Kurbonbekova PK. A modern view on the etiopathogenesis of chloasma. Vestnik Avitsenny. 2020;22(4):621-628. (In Russ.). https://doi.org/10.25005/2074-0581-2020-22-4-621-628
  10. Kruglova LS, Ikonnikova EV. Nonneoplastic hyperpigmentation of the skin: modern views on methods of correction. Rossiyskij zhurnal kozhnykh i venericheskikh boleznej. 2017;20(4):248-251. (In Russ.). https://doi.org/10.18821/1560-9588-2017-20-4-248-251
  11. Kwon SH, Na JI, Choi JY, Park KC. Melasma: Updates and perspectives. Exp Dermatol. 2019;28(6):704-708.  https://doi.org/10.1111/exd.13844
  12. Rendon M, Berneburg M, Arellano I, Picardo M. Treatment of melasma. J Am Acad Dermatol. 2006;54(5 Suppl 2):S272-281.  https://doi.org/10.1016/j.jaad.2005.12.039
  13. Sarkar R, Katoch S. Chemical Peels in Treatment of Melasma. Dermatol Clin. 2024;42(1):21-32.  https://doi.org/10.1016/j.det.2023.06.003
  14. McKesey J, Tovar-Garza A, Pandya AG. Melasma Treatment: An Evidence-Based Review. Am J Clin Dermatol. 2020;21(2):173-225.  https://doi.org/10.1007/s40257-019-00488-w
  15. Dunbar S, Posnick D, Bloom B, Elias C, Zito P, Goldberg DJ. Energy-based device treatment of melasma: An update and review of the literature. J Cosmet Laser Ther. 2017;19(1):2-12.  https://doi.org/10.1080/14764172.2016.1229485
  16. Tuknayat A, Thami GP, Bhalla M, Sandhu JK. Autologous intralesional platelet rich plasma improves melasma. Dermatol Ther. 2021;34(2):e14881. https://doi.org/10.1111/dth.14881
  17. Pixley JN, Cook MK, Singh R, Larrondo J, McMichael AJ. A comprehensive review of platelet-rich plasma for the treatment of dermatologic disorders. J Dermatolog Treat. 2023;34(1):2142035. https://doi.org/10.1080/09546634.2022.2142035
  18. Kim DS, Park SH, Park KC. Transforming growth factor-beta1 decreases melanin synthesis via delayed extracellular signal-regulated kinase activation. Int J Biochem Cell Biol. 2004;36(8):1482-1491. https://doi.org/10.1016/j.biocel.2003.10.023
  19. Hofny ERM, Abdel-Motaleb AA, Ghazally A, Ahmed AM, Hussein MRA. Platelet-rich plasma is a useful therapeutic option in melasma. J Dermatolog Treat. 2019;30(4):396-401.  https://doi.org/10.1080/09546634.2018.1524821
  20. Deng T, Cheng F, Guo S, Cheng H, Wu J. Application of PRP in Chloasma: A Meta-Analysis and Systematic Review. Comput Intell Neurosci. 2022; 2022:7487452. https://doi.org/10.1155/2022/7487452
  21. Sirithanabadeekul P, Dannarongchai A, Suwanchinda A. Platelet-rich plasma treatment for melasma: A pilot study. J Cosmet Dermatol. 2020;19(6): 1321-1327. https://doi.org/10.1111/jocd.13157
  22. Kim C, Gao JC, Moy J, Lee HS. Fractional CO2 laser and adjunctive therapies in skin of color melasma patients. JAAD Int. 2022;8:118-123.  https://doi.org/10.1016/j.jdin.2022.02.010
  23. Jalaly NY, Valizadeh N, Barikbin B, Yousefi M. Low-power fractional CO₂ laser versus low-fluence Q-switch 1,064 nm Nd:YAG laser for treatment of melasma: a randomized, controlled, split-face study. Am J Clin Dermatol. 2014;15(4):357-363.  https://doi.org/10.1007/s40257-014-0080-x
  24. Tawfic SO, Abdel Halim DM, Albarbary A, Abdelhady M. Assessment of combined fractional CO2 and tranexamic acid in melasma treatment. Lasers Surg Med. 2019;51(1):27-33.  https://doi.org/10.1002/lsm.23032
  25. Tuknayat A, Bhalla M, Thami GP. Clinical efficacy of platelet rich plasma in Chloasma. Journal of the Dermatology Nurses’ Association. 2020;12(2): 2431-2436.
  26. Gamea MM, Kamal DA, Donia AA, Hegab DS. Comparative study between topical tranexamic acid alone versus its combination with autologous platelet rich plasma for treatment of melasma. J Dermatolog Treat. 2022;33(2): 798-804.  https://doi.org/10.1080/09546634.2020.1781755

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.